US OptionsDetailed Quotes
BMY240712P41500
- 0.85
- +0.38+80.85%
15min DelayClose Jul 12 15:59 ET
0.93High0.54Low
0.54Open0.47Pre Close54 Volume126 Open Interest41.50Strike Price4.19KTurnover88.64%IV-0.47%PremiumJul 12, 2024Expiry Date1.04Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8661Delta0.2359Gamma36.78Leverage Ratio-0.4070Theta-0.0002Rho-31.86Eff Leverage0.0022Vega
Bristol-Myers Squibb Stock Discussion
good news with share drops doent understand this share.
so many good news. but the share just never go up and yet keep on dropping .
📌 This week’s PDUFAs:
$Merck & Co(MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
$CAVA Group(CAVA.US)$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US)$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US)$ : “There’s g...
$Harmony Biosciences(HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US)$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
$Bristol-Myers Squibb(BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US)$
Despite recent performance s...
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...
No comment yet